Accounts Receivable, after Allowance for Credit Loss, Current of Monte Rosa Therapeutics, Inc. for 30 Jun 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Monte Rosa Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate for 30 Jun 2024.
  • Monte Rosa Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Jun 2024 was $9,000,000.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)

Monte Rosa Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $9,000,000 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.